SAB Biotherapeutics: Bollinger Bands Narrowing, KDJ Death Cross on 15-Min Chart

SAB Biotherapeutics' 15-minute chart has exhibited a narrowing of Bollinger Bands and a KDJ Death Cross at 08/06/2025 09:45. This indicates a decrease in the magnitude of stock price fluctuations and a shift in momentum towards the downside, suggesting a potential further decrease in stock price.

SAB Biotherapeutics Inc. (SABS) is expected to report a loss of 80 cents per share for the quarter ending June 30, 2025, according to analyst estimates [1]. The company is anticipated to show a fall in quarterly revenue, which has been a consistent trend over the past quarters. Previous quarters have seen mixed performance with some beats and misses, indicating a volatile earnings history [1].

Analysts maintain a "buy" rating on SABS shares, with 5 "strong buy" or "buy" recommendations and no "hold," "sell," or "strong sell" ratings. The mean earnings estimate from analysts has remained unchanged over the last three months, suggesting a stable outlook despite the expected loss [1].

Technical indicators also suggest a potential downward trend for SABS. The 15-minute chart exhibits a narrowing of Bollinger Bands and a KDJ Death Cross on August 6, 2025, at 09:45. These indicators imply a decrease in the magnitude of stock price fluctuations and a shift in momentum towards the downside, suggesting a potential further decrease in stock price [1].

Additionally, SABS has received $175 million in funding from a group of investors, which may provide some financial stability for the company [2]. However, the company's recent acquisition of Vigil Neuroscience and the ongoing dispute over drug prices in the industry could impact its stock performance [2].

The current median 12-month price target for SABS is $11.50, which is approximately 80.2% above its last closing price of $2.28. This indicates a positive outlook from Wall Street, but the company's earnings performance and technical indicators suggest caution [1].

Investors should closely monitor SAB Biotherapeutics Inc.'s earnings report on August 6, 2025, and consider the potential impact of the narrowing Bollinger Bands and KDJ Death Cross on the company's stock price.

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3TW2ZP:0-sab-biotherapeutics-inc-expected-to-post-a-loss-of-80-cents-a-share-earnings-preview/
[2] https://www.marketscreener.com/news/sanofi-completes-acquisition-of-vigil-neuroscience-ce7c5ed8d080f32c